Compare POLA & LYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | POLA | LYRA |
|---|---|---|
| Founded | 1979 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical/Dental Instruments |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0M | 5.6M |
| IPO Year | 2016 | 2020 |
| Metric | POLA | LYRA |
|---|---|---|
| Price | $1.44 | $1.89 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | ★ 4.0M | 142.8K |
| Earning Date | 11-19-2025 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $8,326,000.00 | $600,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $163.16 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.31 | $1.60 |
| 52 Week High | $5.75 | $37.50 |
| Indicator | POLA | LYRA |
|---|---|---|
| Relative Strength Index (RSI) | 39.81 | 35.99 |
| Support Level | $1.45 | $1.73 |
| Resistance Level | $1.63 | $2.05 |
| Average True Range (ATR) | 0.28 | 0.29 |
| MACD | -0.02 | 0.04 |
| Stochastic Oscillator | 1.09 | 25.51 |
Polar Power Inc is engaged in designing, manufacturing, and selling DC power generators, renewable energy, and cooling systems for applications in the telecommunications market and, to a lesser extent, in other markets, including military, electric vehicle, marine, and industrial. The company's products include DC generators, backup DC generators, hybrid power systems, Li-Ion battery systems, Marine DC generators, and others. The company's geographical presence is in the United States, Canada, Australia and South Pacific Islands, Asia, Europe and Middle East, United Kingdom, Other North America, South Africa, and others.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.